On June 09, 2014, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced that it filed a provisional patent application in the United States for the use of its drug, aramchol, for the treatment of lipodystrophy. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), weekly performance is -6.53%. On last trading day company shares ended up $9.30. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), distance from 50-day simple moving average (SMA50) is 14.68%.
Heat Biologics Inc (NASDAQ:HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced that its Dose Escalation Committee has approved the expansion of the first cohort to full enrollment in its ongoing Phase 1/2 study of HS-410 (Vesigenpumatucel-L) for the treatment of bladder cancer. The Committee unanimously agreed to expand the cohort to the full nine patients without delay. Heat Biologics Inc (NASDAQ:HTBX), advanced 8.23% in last trading session and ended the day on $5.39. HTBX, return on assets is -45.90%. Heat Biologics Inc (NASDAQ:HTBX), quarterly performance is -26.67%.
On June 17, 2014, Mirati Therapeutics, Inc. (NASDAQ:MRTX), said that mocetinostat, the company’s spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration as a treatment for myelodysplastic syndrome. Mirati Therapeutics, Inc. (NASDAQ:MRTX), shares moved up 5.24% in last trading session and was closed at $22.49, while trading in range of $21.60 – 22.97. Mirati Therapeutics, Inc. (NASDAQ:MRTX), year to date (YTD) performance is 35.24%.
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced that at its annual meeting of stockholders held on June 12, 2014, stockholders voted in favor of changing the company’s corporate name to CASI Pharmaceuticals Inc (NASDAQ:CASI), The name change will occur on June 16, 2014 with the Company’s common stock trading on NASDAQ under the new symbol “CASI” and the rollout of a new website www.casipharmaceuticals.com. CASI Pharmaceuticals Inc (NASDAQ:CASI), ended the last trading day at $1.78. Company weekly volatility is calculated as 8.60% and price to cash ratio as 3.39. CASI Pharmaceuticals Inc (NASDAQ:CASI), showed a negative weekly performance of 4.81%.
Leave a Reply